In contrast, the Nrf2 activator, AI-1, markedly increased the protein and transcript levels of ATF4 in breast cancer cells either treated with CB-839 or deprived of glutamine (Figs. 4F, G, and S3C). Here, ATF4 is linked to breast carcinoma.